Consort Medical plc
Consort Medical plc, a leading player in the pharmaceutical and medical device industry, is headquartered in Great Britain. Founded in 1984, the company has established itself as a key innovator in drug delivery systems and medical devices, serving a global market with a strong presence in Europe and North America. Specialising in the development of advanced inhalation devices and other drug delivery technologies, Consort Medical is renowned for its commitment to quality and innovation. Their core products, including the Bespak and Aesica brands, are designed to enhance patient outcomes through precision and reliability. With a robust market position, Consort Medical has achieved significant milestones, including strategic partnerships and a focus on sustainability, solidifying its reputation as a trusted partner in the healthcare sector.
DitchCarbon Score
How does Consort Medical plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Consort Medical plc's score of 18 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Consort Medical plc's reported carbon emissions
Consort Medical plc, headquartered in Great Britain, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is identified as a current subsidiary and has inherited its climate commitments and data from its parent organization, which is not specified in the provided information. As of now, Consort Medical plc has not established any documented reduction targets or climate pledges, nor does it appear to participate in initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). This lack of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the context of the industry, it is increasingly important for companies to set measurable targets and report on their carbon emissions to align with global climate goals. As Consort Medical plc continues to evolve, it may consider adopting such initiatives to enhance its sustainability profile and contribute to broader climate action efforts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Consort Medical plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
